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FRAX PREDICTIONS IN UPPER EXTREMITY FRACTURE AND NON-
FRACTURE PATIENTS 
 
THANY SEYOK 
 
ABSTRACT 
 
 Osteoporosis is the most common human bone disease and a growing public 
health problem. Worldwide, 9 million fractures due to osteoporosis occur annually. 
Fracture is the main burden of the disease and is linked with significant morbidity and 
mortality. A history of upper extremity fragility fracture is known to contribute to 
increased risk of subsequent fractures. In this study, we compared the estimated FRAX 
10-year probability of major osteoporotic fracture and hip fracture between upper 
extremity (UE) fracture and non-fracture patients. In addition, we assessed differences in 
demographics and osteoporosis evaluation between the two groups, and we report the 
prevalence of lab abnormalities among UE fragility fracture patients evaluated in our 
fracture liaison service (FLS). A total of 243 patients from Brigham and Women’s 
Faulkner Hospital were recruited to participate in the study. UE fracture patients were 
recruited from our FLS, and UE non-fracture patients were recruited from the UE clinic. 
Overall 10-year probability of major osteoporotic and hip fracture was higher in upper 
extremity fracture patients than upper extremity non-fracture patients (19.23 versus 9.23, 
p <0.001 and 4.26 versus 1.54. p < 0.001 respectively). When excluding fragility fracture 
history, 10-year probability of major osteoporotic fracture and hip fracture were similar 
  vi 
between upper extremity fracture and non-fracture patients (10.59 versus 9.23, p = 0.095 
and 1.88 versus 1.54, p = 0.215 respectively). The proportion of osteoporosis evaluation 
via bone mineral density assessment was higher in upper extremity fracture patients 
compared to upper extremity non-fracture patients (p < 0.001). However, the proportion 
of upper extremity fracture patients on osteoporosis medication was low and not different 
than upper extremity non-fracture patients (p < 0.079). Our results highlight history of 
fragility fracture as an important driver in subsequent fracture risk. UE fracture and non-
fracture patients harbor similar fracture clinical risk factors, with the exception of fracture 
history, and are similarly at risk for future hip fracture and major osteoporotic fracture. 
Our results suggest close osteoporosis evaluation of older upper extremity non-fracture 
patients is warranted. 
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INTRODUCTION 
 
 
Osteoporosis 
Osteoporosis is a systemic skeletal disorder characterized by low bone mass and 
microarchitectural disruption resulting in skeletal fragility and increased risk for 
fractures. Osteoporosis is the most common human bone disease affecting an estimated 
200 million people worldwide (Cooper, Campion, & Melton, 1992). In the United States, 
an estimated 10.2 million adults over the age of 50 have osteoporosis, and another 43.4 
million are at risk for developing osteoporosis due to harboring osteopenia; low bone 
mass (Wright et al., 2014). As the population in the United States continues to age, the 
prevalence of osteoporosis is projected to rise as much as 50% by 2025 (Kling, Clarke, & 
Sandhu, 2014). 
 Fracture is the major burden of osteoporosis and drastically changes the quality 
of life for patients and their families due to limitation of ambulation, depression, loss of 
independence, chronic pain, and economic burden (Adachi et al., 2010). Annually, 
approximately 9 million fractures occur worldwide due to osteoporosis, with the majority 
of them occurring in developed countries (O. Johnell & Kanis, 2006). The economic 
burden resulting as a consequence of fragility fractures are enormous for western 
populations and are expected to dramatically increase in Asia, Latin America and the 
Middle East as populations continue to age. The total direct cost of fragility fractures in 
Europe was 32 billion euros in 2005 (J. A. Kanis & Johnell, 2005). In the USA, the 
combined cost of all fragility fractures in 2002 was $20 billion (Steven R. Cummings & 
 2 
Melton, 2002). In 2006, China spent an estimated $1.6 billion on hip fracture care, which 
is projected to increase to $265 billion by 2050 (Mithal, Bansal, Kyer, & Ebeling, 2014). 
Being a silent disease, many patients are unaware they have osteoporosis until they 
sustain a fragility fracture. 
 
Fragility Fracture 
Fragility fractures, also referred to as osteoporotic or low-trauma fractures, are 
fractures that result from a fall of standing height or less without major trauma. Among 
older adults in the United States, fragility fractures have become nearly epidemic with an 
estimated 2 million occurring each year (Singer et al., 2015). Fragility fractures are more 
common in women than men, due in part to the decline in estrogen, which has a 
protective effect on bone mass, associated with menopause in women (Riggs, Khosla, & 
Melton, 1998). The lifetime risk for fragility fracture is 40% to 50% and 13% to 22% for 
women and men, respectively (Olof Johnell & Kanis, 2005). Half of all women over 50 
years old and one-fifth of all men over 50 years old are expected to experience a fragility 
fracture in their lifetime (J. A. Kanis & Glüer, 2000). Fragility fractures typically occur at 
the vertebrae (spine), proximal femur (hip), proximal humerus (shoulder), or distal radius 
(wrist).  
Vertebral fragility fractures (VFFs) are the most common type of fragility 
fractures and serve as strong predictors of future fractures at any site independent of bone 
mineral density (BMD) (P. D. Delmas et al., 2003). VFFs occur in 30% to 50% of people 
over the age of 50 years old and significantly increases the risk for subsequent VFFs 
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(Briggs, Greig, & Wark, 2007; Melton et al., 1993), resulting in a phenomenon referred 
to as the “vertebral fracture cascade”.  VFFs can occur independent of a fall, and 
symptoms include chronic back pain, height loss, and spinal deformity. Diagnosis is 
confirmed via imaging performed specifically to examine the spine, or incidentally from 
images performed for other clinical indications, such as abdominal computed tomography 
(CT) or magnetic resonance imaging (MRI) (Adams, 2016). Approximately 30% of VFFs 
are asymptomatic and do not come to clinical attention (Ensrud, 2013). In addition, it has 
been reported that VFFs are generally under-diagnosed radiographically by radiologists 
worldwide (Pierre D. Delmas et al., 2005). Therefore, a large proportion of patients with 
VFFs may not be receiving appropriate osteoporosis evaluation or treatment putting them 
at higher risk for severe fractures such as hip fractures. 
Among fragility fractures seen in men and women over the age of 50, hip 
fractures cause substantial morbidity and mortality (Haleem, Lutchman, Mayahi, Grice, 
& Parker, 2008). Worldwide, it is estimated over 1.7 million people aged 50 years old or 
older suffer from hip fractures, and that number is expected to increase to 6.3 million by 
2050 (Cooper et al., 1992). In patients aged 65 and over that sustain a hip fracture, the 
one-year mortality risk has been estimated to be 12% to 37%, and the 5-year mortality 
risk can reach 60% in some elderly populations (Tajeu et al., 2014). Among those that 
survive a hip fracture incident, half do not regain their pre-fracture functionality, and 
approximately 20% require some form of long-term care (Office of the Surgeon General 
(US), 2004). Hip fractures are seldom the initial fracture event seen in osteoporotic 
patients. It has been reported that approximately half of hip fracture patients suffered 
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prior fracture events before sustaining the hip fracture (Edwards, Bunta, Simonelli, 
Bolander, & Fitzpatrick, 2007; Port et al., 2003).  Indeed, the initial fragility fracture 
should serve as a warning and lead to osteoporosis screening and treatment initiation, if 
warranted, to prevent subsequent refractures (Cosman et al., 2014). 
The most common sites for upper extremity fragility fractures are in the distal 
radius and proximal humerus. Distal radius fractures often occur as a result of attempting 
to provide protection during a fall by using the hands, and proximal humerus fractures 
often occur as a result of direct falls onto the shoulder joint (Kelsey, Browner, Seeley, 
Nevitt, & Cummings, 1992). Distal radial fractures are more common in women who 
have low BMD, are more active, and relatively healthy. Proximal humeral fractures are 
more common in women who have a low BMD and who are less active (Kelsey et al., 
1992). The incidence of distal radial fractures is approximately 100–130 per 100,000 
people per year and 300–400 per 100,000 people per year for men and women, 
respectively (Kelsey et al., 1992). In men, the incidence of distal radial fractures does not 
increase with age. In women, the incidence increases throughout their late 50s and tends 
to decrease after the age of 85 (Kelsey et al., 1992). Although the direct consequences of 
distal radius and proximal humerus fractures are less severe than hip fractures, they serve 
as predictors for future fractures, including hip fractures (Jung et al., 2019). One study 
estimated that a single proximal humeral fracture increases the risk of a subsequent hip 
fracture more than five times in the first year after the humeral fracture (Clinton et al., 
2009). Indeed, early signs of upper fractures should trigger appropriate evaluation and 
treatment for osteoporosis to prevent subsequent fractures. 
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Fragility Fracture Risk Factors 
Low bone strength is one of the strongest predictors for fragility fracture. 
Properties that make up bone strength include bone mineral density (BMD), bone 
microarchitecture, bone size and shape, bone turnover, and degree of bone mineralization 
(Ahlborg, Johnell, Turner, Rannevik, & Karlsson, 2003). The most widely used method 
for measuring BMD is Dual-energy x-ray absorptiometry (DXA). DXA measures bone 
mineral content (in grams) and bone area (in square centimeters) and calculates an areal 
BMD, expressed in g/cm2. DXA also reports BMD as a T-score, defined as the difference 
in number of standard deviations (SDs) from the mean BMD of a normally distributed 
healthy adult reference population, typically an average healthy 30-year old adult 
(“Assessment of fracture risk and its application to screening for postmenopausal 
osteoporosis. Report of a WHO Study Group,” 1994). In addition, BMD is also reported 
as a Z-score, which is calculated similarly to the T-score but uses an age-matched normal 
population for comparison (Lewiecki et al., 2004). DXAs are typically performed at 
skeletal sites associated with major clinical consequences if a fracture were to occur at 
that site. These skeletal sites include the spine, hip, and forearm. Numerous studies have 
demonstrated that low BMD measured by DXA at any skeletal site can predict fragility 
fracture (Black et al., 1992; Olof Johnell et al., 2005; Leslie, Tsang, Caetano, Lix, & 
Manitoba Bone Density Program, 2007; Stone et al., 2003). However, site-specific 
measurements are typically better predictors for fractures at their respective sites 
(Marshall, Johnell, & Wedel, 1996). For example, results from a DXA of the hip are a 
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better predictor for future hip fracture than results from a DXA of the forearm or spine. In 
general, prior studies have shown that a one standard deviation decrease in BMD results 
in an approximately twofold increase in risk of fragility fracture (Cauley et al., 2007; 
Leslie et al., 2007).  
In addition to BMD, a number of clinical risk factors also provide information on 
fracture risk. These clinical risk factors include falls, advancing age, family history of hip 
fracture, smoking history, excessive alcohol consumption, low body weight, history of 
fragility fracture, glucocorticoid therapy, rheumatoid arthritis and secondary osteoporosis 
(John A. Kanis, 2002).  
For any given BMD T-score of the femoral neck, the probability of hip fracture 
increases with age (J. A. Kanis et al., 2001). Additionally, a history of fragility fracture in 
a first-degree relative is associated with increased risk of fracture. Cummings et al. 
(1995) reported that parental history of hip fracture was associated with a twofold-
increased risk of hip fracture in women regardless of BMD (S. R. Cummings et al., 
1995). Meta-analyses conducted by Kanis et al. (2005) showed that cigarette smoking is 
associated with decreased BMD and increase risk of fracture (J. A. Kanis et al., 2005). 
The risk was higher in current smokers compared to those with a smoking history. The 
increased risk of fracture associated with excessive alcohol intake is dose dependent 
(John A. Kanis, Johansson, et al., 2005). Consumption of over 28 grams of pure alcohol, 
equal to about over two drinks per day was shown to be associated with an increased risk 
of hip fracture (RR 1.39, 95% CI 1.08-1.79) (Berg et al., 2008).  
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Low body weight, less than 58kg or 127lb, is associated with increased risk of 
osteoporosis and fracture (Green, Colón-Emeric, Bastian, Drake, & Lyles, 2004). In 
women, height increase and weight loss after 50 increases the risk of hip fracture, while 
weight gain decreases the risk of hip fracture (Meyer, Falch, O’Neill, Tverdal, & Varlow, 
1995). Interestingly, the method in which weight is lost may affect bone physiology. A 
randomized trial reported subjects who lost weight via calorie restriction had decreased 
total hip BMD, while subjects who lost the same amount of weight via exercise without 
calorie restriction had no changes in BMD (Villareal et al., 2006). 
A history of a fragility fracture is an important risk factor for subsequent fracture 
in men and women. Kanis et al. (2004) conducted a meta-analysis of 11 prospective 
cohort studies from around the world on fracture risk in men and women with a history of 
fracture and reported increased risks for any fracture (relative risk (RR) 1.8, 95% CI 1.6-
1.9), osteoporotic fracture (RR 1.8, 95% CI 1.6-1.9), and hip fracture (RR 1.6, 95% CI 
1.3-2.0) (J. A. Kanis et al., 2004). A history of a high-trauma fracture may also be a risk 
factor for subsequent fracture in women. A nine-year study of 8022 women participating 
in The Study of Osteoporotic Fractures reported an increased risk of subsequent fracture 
in women with a previous history of high and low trauma non-spine fractures compared 
with women who had not had such fractures (Mackey et al., 2007). The risk of 
subsequent fracture was 34 percent (95% CI 7-67) and 31 percent (95% CI 20-43) higher 
among women with a history of high and low trauma fracture, respectively. 
Glucocorticoid therapy is associated with marked increase in risk of bone loss and 
fracture (van Staa, Leufkens, & Cooper, 2002). Glucocorticoids particularly increases the 
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risk of vertebral fracture during the earlier stages of the glucocorticoid therapy, which are 
typically associated with a rapid phase of bone loss (Angeli et al., 2006). BMD levels of 
fracture patients on glucocorticoid therapy are typically higher than fractures seen in 
patients with postmenopausal osteoporosis (Canalis, Mazziotti, Giustina, & Bilezikian, 
2007). Fractures have been reported in as many as 30 to 50 percent of glucocorticoid 
users, and the incidence of fracture are higher with advanced age, larger doses, and 
longer durations of glucocorticoid therapy (Canalis et al., 2007; Curtis et al., 2006). 
However, an increased risk of fracture has also been reported with low doses of 
prednisone, a commonly prescribed glucocorticoid, or its equivalent even as low as 2.5 to 
7.5 mg daily and with short-term use, defined as less than 30 days of use (Van Staa, 
Leufkens, Abenhaim, Zhang, & Cooper, 2000; Waljee et al., 2017). The detrimental 
effects of glucocorticoid on bone result from its direct effects on osteoblasts and 
osteoclasts. Osteoblasts and osteoclasts are bone cells responsible for bone formation and 
bone resorption respectively. Glucocorticoids increase osteoclast activity and reduce 
osteoblast activity (Figure 1) (Canalis et al., 2007). The risk of bone loss is typically 
significantly greater in the first months of use followed by slower loss of bone with 
continued use (Canalis et al., 2007). With continued use, osteoclast-mediated resorption 
of bone slows, and suppression of bone formation becomes the major effect on bone. In 
addition, glucocorticoids also decrease intestinal calcium absorption by opposing the 
actions of vitamin D and by decreasing the expression of calcium channels in the 
duodenum (Huybers, Naber, Bindels, & Hoenderop, 2007). 
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Figure 1. Glucocorticoid effects on BMD.  
 
In addition to BMD and non-BMD risk factors, medical diseases associated with 
low BMD also increase fracture risk. These medical diseases include rheumatoid arthritis 
(RA), inflammatory bowel disease (IBS), celiac disease, cystic fibrosis (CF), 
hyperthyroidism, type 1 and 2 diabetes, renal diseases, and sickle cell disease (Deal, 
 10 
2012; Ensrud et al., 2007; Grey et al., 2008; Kemppainen et al., 1999; Targownik et al., 
2013; Thong et al., 2018; Vanderhave, Perkins, Scannell, & Brighton, 2018; Vestergaard 
& Mosekilde, 2003). These diseases typically contribute to low BMD through underlying 
inflammation, malabsorption, renal excretion of calcium, or secondarily via medications 
used to treat these diseases. Other risk factors include vitamin D deficiency, dementia, 
history of breast cancer, and use of select medications including androgen deprivation 
agents, aromatase inhibitors, proton pump inhibitors, selective serotonin reuptake 
inhibitors, thiazolidinediones, and anticonvulsants (Lakkireddy, Mudavath, Karra, & 
Arora, 2019; Mughal, Inderjeeth, & Inderjeeth, 2019; Watts, 2017). 
Potential risk factors for increased fracture have also been identified. These 
include depression, mild asymptomatic hyponatremia (serum sodium <135 mEq/L), 
aortic calcification on computed tomography (CT) scan, high levels of inflammation 
markers, high dietary retinol intake, sedentary lifestyle, vitamin B12 deficiency, high 
homocysteine concentrations, large amounts of caffeine consumption, and intake of 
carbonated beverages (S. R. Cummings et al., 1995; Gankam Kengne, Andres, Sattar, 
Melot, & Decaux, 2008; Gregg, Cauley, Seeley, Ensrud, & Bauer, 1998; Leboff et al., 
2009; Macêdo, Carvalho, Cavalcanti, & Freitas, 2017; Mezuk, Eaton, & Golden, 2008; 
Schett et al., 2006; Schulz, Arfai, Liu, Sayre, & Gilsanz, 2004; Tucker et al., 2006; Zhang 
et al., 2017) 
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Table 1. Summary of fragility fracture risk factors 
 
  
Clinical Risk 
Factors 
Advanced age 
Familial hip fracture 
Smoking history  
Excessive alcohol intake  
Low body weight  
Fragility fracture history  
Glucocorticoid therapy  
Vitamin D deficiency  
Medical Diseases Rheumatoid arthritis 
Inflammatory bowel syndrome 
Celiac disease 
Cystic fibrosis 
Hyperthyroidism 
Type I and II diabetes 
Renal diseases  
Sickle cell  
Potential Risk 
Factors 
Depression  
Mild asymptomatic hyponatremia  
Aortic calcification  
High inflammation markers  
High retinol intake  
Sedentary lifestyle  
Vitamin B12 deficiency  
High homocysteine levels  
Excessive caffeine intake  
Intake of carbonated beverages  
 
 
 
Osteoporosis Screening 
 The World Health Organization (WHO) published the first diagnostic criteria for 
osteoporosis in 1994 using epidemiological data (Table 2). The WHO defines normal 
bone as BMD T-scores no more than 1 SD below the average, osteopenia as BMD T-
scores 1 to 2.5 SDs below the average, osteoporosis as BMD T-scores greater than 2.5 
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SDs below the average, and severe osteoporosis as BMD T-scores greater than 2.5 SDs 
below average with a history of one or more fragility fractures (J. A. Kanis, 1994). 
 
Table 2. WHO diagnostic criteria 
 
Classification BMD 
Normal A value for BMD within 1.0 SD of the young adult 
female reference average (T-score greater than or 
equal to -1.0 SD). 
 
Osteopenia (low 
bone mass) 
A value for BMD more than 1.0 but less than 2.5 
SD below the young adult female reference average 
(T-score less than -1 and greater than -2.5 SD). 
 
Osteoporosis A value for BMD 2.5 or more SD below the young 
adult female reference average (T-score less than or 
equal to -2.5 SD). 
 
Severe osteoporosis A value for BMD more than 2.5 SD below the 
young adult female reference average in the 
presence of one or more fragility fractures (T-score 
less than or equal to -2.5 SD). 
 
*BMD = bone mineral density; DXA = dual-energy x-ray absorptiometry; SD = 
standard deviation 
 
 
 
The National Osteoporosis Foundation (NOF) and United States Preventive 
Services Task Force (USPSTF) both recommend DXA BMD screening in all 
postmenopausal women age 65 years or older regardless of risk factors (Cosman et al., 
2014; US Preventive Services Task Force et al., 2018). There is no universal agreement 
regarding DXA BMD screening in older men. The USPSTF found insufficient evidence 
to make a recommendation for screening men (US Preventive Services Task Force et al., 
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2018). However, other groups including the NOF have recommended DXA BMD 
screening for all men older than 70 years old (Cosman et al., 2014). For men and women 
under 65 years old, DXA BMD screening recommendations vary. For women younger 
than 65 years, The USPSTF recommends DXA BMD screening for individuals who are 
at increased risk for osteoporosis as determined by clinical risk assessment tools (US 
Preventive Services Task Force et al., 2018).  
The most widely used tool to assess fracture risk is FRAX®. The FRAX® tool 
was developed in 2008 by researchers at The University of Sheffield to estimate fracture 
risk in untreated patients between the ages of 40 and 90 years old using easily obtainable 
fracture clinical risk factors and femoral neck DXA BMD (J. A. Kanis, Johnell, Oden, 
Johansson, & McCloskey, 2008). FRAX® is based on data collected from large, 
prospective, observational studies that evaluated clinical risk factors, BMD, and fractures 
in men and women of different ethnicities and from different regions of the world (John 
A. Kanis, Borgstrom, et al., 2005). FRAX® has been validated in 26 independent cohorts 
comprised of mainly women (Marques et al., 2015). The statistical power of this large 
dataset allows estimation of a 10-year probability of hip fracture, and major osteoporotic 
fracture at the spine, forearm, and shoulder from an individual’s set of risk factors. 
Clinical risk factors accounted for by the tool include country of residence, ethnicity, age, 
sex, weight, height, fragility fracture history, parental hip fracture history, current 
smoking status, glucocorticoid use, rheumatoid arthritis diagnosis, secondary 
osteoporosis diagnosis, and excessive alcohol consumption. In addition, the FRAX® tool 
can also be used to assess fracture risk when a femoral neck BMD is not available. 
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FRAX® predictions solely on clinical factors have been shown to provide the same risk 
predictions as FRAX® predictions with both clinical factors and femoral neck BMD in 
most cases (Gadam, Schlauch, & Izuora, 2013). This is particularly useful in world 
regions that do not have access to BMD screening technologies. The FRAX® tool can be 
accessed online for free at https://www.sheffield.ac.uk/FRAX/. The FRAX® tool is also 
available on mobile devices and newer DXA software. 
 
 
Figure 2. FRAX® online user interface 
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Other fracture risk assessment tools include the Garvan Fracture Risk Calculator 
and QFractureScores, which are country specific alternatives to FRAX®. The Garvan 
calculator was derived using the Australian Dubbo cohort of approximately 2000 men 
and women, and it predicts osteoporotic fracture risk over 5 or 10 years (Nguyen, Frost, 
Center, Eisman, & Nguyen, 2008). The 5-year fracture risk prediction is thought to be 
more useful for patients at older ages. To estimate osteoporotic fracture risk, the Garvan 
calculator takes into account age, sex, history of fractures since the age of 50, falls over 
the last 12 months, and BMD measureme. The tool is accessible freely online at 
https://www.garvan.org.au/promotions/bone-fracture-risk/calculator/ (Figure 3). The 
QFractureScores was developed and validated through studying primary care populations 
in the United Kingdom (Hippisley-Cox & Coupland, 2009). The tool estimates risk of 
osteoporotic fracture over 1 to 10 years and takes into account 30 fracture clinical risk 
factors (Figure 4). However, the tool does not incorporate BMD measurements into their 
estimates. QFractureScores is also free and accessible at https://qfracture.org/.  
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Figure 3. Garvan Fracture Risk Calculator online user interface  
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Figure 4. QFractureScores online user interface 
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Despite guidelines and assessment tools available for osteoporosis screening, 
there remains an osteoporosis care gap. Studies indicate that among men and women who 
are at high risk of fracture, only a minority actually receive treatment. In patients who 
sustain a fragility fracture, less than 20 percent received therapies to reduce the risk of 
fracture in the year following the fracture (L. Giangregorio, Papaioannou, Cranney, 
Zytaruk, & Adachi, 2006; John A. Kanis, Svedbom, Harvey, & McCloskey, 2014). In a 
prospective observational study of over 60,000 postmenopausal women aged 55 and 
older recruited from primary care practices in 10 countries, over 80 percent of women 
with a fragility fracture did not receive osteoporosis treatment (Greenspan et al., 2012). 
Furthermore, among patients that do initiate osteoporosis treatment, successful 
osteoporosis management is hindered by poor patient adherence to prescribed therapies 
(Brookhart et al., 2007; Gold & Silverman, 2006). Fracture liaison clinics have emerged 
as a potential solution to the osteoporosis care gap. 
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Fracture Liaison Services 
Fracture Liaison Services (FLS), also referred to as Fracture Liaison Clinics, are 
secondary fracture prevention services implemented by health care systems for the 
treatment of osteoporotic patients. FLS operates by identifying patients presenting with 
fragility fractures, referring them for the necessary assessment of their bone health and 
fracture risk, and recommending or initiating appropriate treatment to prevent further 
fractures, especially more serious ones such as hip fractures.  
One of the first FLS programs, implemented in 1999 across two Health Service 
Trusts in Glasgow, Scotland, reported notable improvements in identifying and 
evaluating patients with fractures (McLellan, Gallacher, Fraser, & McQuillian, 2003). 
The authors reported that within the first 18 months of FLS implementation, more than 
4,600 fracture patients were identified and evaluated for osteoporosis, which represents 
almost all fractures estimated to occur in the population served by these two hospitals. 
Prior to implementation of the FLS, less than 10% of fracture patients were referred for 
osteoporosis evaluation. In the USA, the Kaiser Permanente Southern California (Kaiser 
SCAL) Healthy Bones FLS Program started in 2002 and reported a 37.2% reduction in 
hip fractures resulting in cost-savings of over $30.8 million in the year 2006 alone (Dell, 
Greene, Schelkun, & Williams, 2008). Various FLS models have been implemented 
worldwide and have been shown to reduce the risk of future fractures and post-fracture 
mortality through efficiently identifying fracture patients, providing (BMD) and fracture 
risk assessment, increasing both the initiation and adherence of osteoporosis treatment, 
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providing ongoing monitoring and support, and providing fall prevention initiatives 
(Ganda et al., 2013; Chih-Hsing Wu et al., 2018). 
The FLS models available today vary considerably in their structure and in the 
services they provide. FLS programs can range from inexpensive mail-based 
interventions that include telephone and print-based patient contacts, to physician 
notification and patient-specific reminders alongside printed treatment guidelines, to 
centralized coordination through an orthogeriatrician or nurse practitioner (C.-H. Wu et 
al., 2018).  
There are a variety of ways to classify FLS programs including one method 
developed by researchers in Australia who classifies them into four categories (A-D) 
(Ganda et al., 2013). In this classification system, type A programs are the most 
comprehensive, utilizing the coordinator as the key player for the identification of 
patients, clinical investigation, and initiation of the appropriate osteoporosis treatment. 
Type B programs are similar, but the patient’s primary care physician initiates the 
treatments instead of the FLS coordinator. In type C programs, patients are educated 
about the need for diagnosis, risk assessment, and possible treatment, and their primary 
care physicians are notified about the patient’s fracture and the need for follow-up and 
risk assessment. In type D programs, patients receive only osteoporosis education and 
there is no outreach to the primary care physician. Type A and type B FLS models have 
the best outcomes and are more cost-effective (Ganda et al., 2013). Despite the different 
models, all FLS models have the unifying goal of identifying high-risk patients and 
referring them for appropriate treatment. 
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Specific Aims 
The majority of fragility fracture patients evaluated by the FLS at Brigham and 
Women’s Faulkner Hospital (BWHF) were patients with upper extremity fractures, 
predominantly proximal humerus and distal radius. History of an upper extremity 
fragility fracture is a risk factor for subsequent fractures, but it is not clear whether upper 
extremity fragility fracture patients are inherently at higher risk for future fractures 
compared to patients who have not experienced an upper extremity fracture, or whether 
the occurrence of fragility fracture is the primary difference between these two groups. 
In this study, we compared the estimated FRAX 10-year probability of major 
osteoporotic fracture and hip fracture between two upper extremity patient cohorts: upper 
extremity fragility fracture patients over age 50 evaluated in the FLS clinic and similarly 
aged patients evaluated in the upper extremity clinic for non-fracture conditions. We 
hypothesized that upper extremity non-fracture patients would have lower FRAX risk for 
major osteoporotic and hip fractures compared to upper extremity fragility fracture 
patients. Our secondary goals were to assess whether these groups differed with respect 
to clinical demographics or rates of osteoporosis evaluation. In addition, we report the 
prevalence of BMD, PTH, and vitamin D lab abnormalities in upper extremity fragility 
fracture patients evaluated in our FLS. 
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METHODS 
 
Participants  
Institutional review board approval was obtained for this cross-sectional study. 
Patients referred to the Fracture Liaison Service (FLS) for osteoporosis evaluation 
following a fragility fracture, and patients evaluated in the upper extremity clinic for non-
fracture upper extremity conditions were approached to fill out the study questionnaires.  
 
Study Outcomes 
Data was collected through two study questionnaires (see Appendix). Recruited 
participants were asked to complete the questionnaires following the completion of their 
appointments at the FLS or upper extremity clinic. The first questionnaire assessed 
fracture risk factors, fracture history, family history of fracture, osteoporosis treatment, 
supplementation, and dietary calcium intake from milk, yogurt, cheese, and calcium 
fortified orange juice. The second questionnaire assessed variables required to calculate a 
FRAX score. The primary outcome of this study was the 10-year probability of hip 
fracture and major osteoporotic fracture calculated by FRAX. Secondary study outcomes 
included estimated daily calcium intake, use of calcium and vitamin D supplementation, 
BMI, DXA history, fall history, smoking or alcohol use, prevalence of secondary 
osteoporosis, glucocorticoid use, DXA T scores, and use of osteoporosis medications 
(Fosamax (Alendronate), Boniva (Ibandranate), Aredia (Pamidronate), Actonel 
(Risedronate), Reclast (Zoledronate), estrogen hormone therapy, Evista (Raloxifene), 
Forteo (Teriparatide), and Prolia (Denosumab)). All data were collected via study 
 23 
questionnaires with the exception of DXA T scores, which were collected via chart 
review. DXA results for spine, hip, femoral neck, and distal radius within one year of the 
FLS or hand clinic visit date were collected for analysis. Analyses of secondary study 
outcome data were conducted with the maximal available data collected (see Appendix). 
 
FRAX Calculator 
In this study, FRAX scores were calculated without BMDs since a limited number 
of upper extremity clinic patients had DXA scans. In addition, we calculated two FRAX 
scores for the FLS group: one including history of fragility fracture (FRAX Score-A) and 
one ignoring history of fragility fracture (FRAX Score-B). FRAX scores were calculated 
using the online tool, which can be found at https://www.sheffield.ac.uk/FRAX/. 
 
Lab Abnormalities 
The prevalence of abnormal DXA, high parathyroid hormone (PTH), and vitamin 
D deficiency was investigated for only patients evaluated in the FLS. Lab data were 
collected through chart review. Since very few patients obtained labs for PTH and 
vitamin D, lab results obtained within one year of the FLS visit date were included in our 
results. Similarly, BMD results from DXA obtained within two years of the FLS visit 
date were included in our results. 
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Statistical Analysis 
Continuous variables were reported as means and assessed for normality before 
analysis with two-tailed Student’s t tests. Nominal variables were analyzed using Fisher’s 
exact tests. FRAX scores and estimated daily calcium intake were assessed for normality 
using Kolmogorov-Smirnov tests and were found to have lognormal distributions. Both 
continuous variables were log transformed before analysis with parametric unpaired t-
tests and reported below as back transformed results. The primary analysis assessed both 
men and women in the analytic cohorts. In addition, a subanalysis of only women in the 
analytic cohorts was conducted.  
A convenience sample was used. The standard significance criterion of α = 0.05 
and standard power criterion of (1-β) = 0.80 was employed for all statistical tests. The 
sample size of 243 (n=129 in the FLS group and 114 in the UE clinic group) affords > 
80% power to detect a difference of 0.36 standard deviations between the two groups. 
Base upon the standard deviation of our FRAX-Score-A data, we will be able to detect a 
difference of 4.19 and 3.05 for hip fracture and major osteoporotic fracture respectively 
between the two groups. For a nominal variable with 10 percent prevalence, our sample 
size affords > 80% power to detect a relative risk of approximately 2.4 (i.e., 10% vs. 
24%). For a variable with higher prevalence (25%), our sample size affords > 80% power 
to detect a relative risk of approximately 1.72 (i.e., 25% vs. 43%). All statistical analyses 
were conducted using GraphPad Prism and are reported as unadjusted results. 
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RESULTS 
 
Subject Characteristics 
During the study period, 219 patients aged 50 years old or over were seen in the 
FLS, and 175 similarly aged patients were seen in the upper extremity clinic. Patients 
evaluated in the FLS for non-upper extremity fragility fractures were excluded from the 
FLS analytic cohort. Patients who did not speak English or failed to complete the study 
questionnaires were also excluded from the analytic cohorts. Additionally, those who 
declined to report ethnicity and race were excluded, as these variables are required in 
order to calculate a FRAX score. After the exclusions, 129 and 114 patients made up the 
analytic cohort for the FLS and upper extremity groups respectively (Figure 5). 
Figure 5. Selection of analytic cohorts 
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The analytic cohorts for the FLS and upper extremity group consisted of 129 and 
114 subjects, respectively. Participants of this study were predominantly older white non-
Hispanic females. The mean age, race and ethnicity distribution, and mean BMI were 
similar between the two groups (Table 3). The upper extremity group had significantly 
more males than the FLS group (26.42% versus 7.75%, p = 0.0001). Of the 129 UE 
fragility fracture patients evaluated in the FLS, 33 percent were proximal humerus 
fractures and 67 percent were distal radius fractures. 
 
Table 3. Analytic cohort characteristics 
 
 FLS (n = 129) UE Clinic (n = 114) 
Mean age (SD) 66.67 (9.80) 67.06 (9.79) 
Gender (%)   
          Female 92.25 73.68 
          Male 7.75 26.32 
Race (%)   
          Asian 1.55 0.88 
          Black or African American 1.55 4.39 
          Hispanic or Latino 4.65 0.00 
          White 92.25 94.74 
Ethnicity (%)   
          Hispanic 4.65 1.75 
          Non-Hispanic 95.35 98.25 
Mean BMI (SD) 27.24 (5.34) 27.34 (6.47) 
*SD = standard deviation; BMI = body mass index; FLS = fracture liaison service; UE = upper extremity 
 
 
Lab Abnormalities 
 Of the 129 fragility fractures evaluated in the FLS, 66 percent and 57 percent had 
vitamin D and PTH lab tests within one year of their FLS visit date, respectively. Among 
the 85 FLS patients who had vitamin D labs, 16 percent were vitamin D deficient 
(defined as levels less than 20 ng/mL), 24 percent were vitamin D insufficient (defined as 
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levels between 20 and 30 ng/mL), and 60 percent were vitamin D sufficient (defined as 
levels greater than 30 ng/mL). Among the 74 FLS patients who had PTH labs, 9 percent 
had high PTH (defined as levels greater than 65 pg/mL). The average vitamin D and PTH 
levels among FLS patients were 35 ng/mL and 49 pg/mL, respectively. 
 
FRAX Scores 
The FRAX Score-A for major osteoporotic fracture was higher in the FLS group 
than the UE group (19.23 (17.58, 21.09) versus 9.23 (8.16, 10.45), p < 0.001). The FLS 
group also had a higher FRAX score for hip fracture (4.26 (3.60, 5.04) versus 1.54 (1.19, 
1.99)), p < 0.001). However, when excluding history of fragility fracture in the FLS 
cohort (FRAX Score-B), there was no difference in FRAX scores for major osteoporotic 
fracture (p = 0.095) and hip fracture (p = 0.215).  In a subanalysis of only women, similar 
results were observed (Table 4). 
Table 4. FRAX Scores 
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Fracture Risk Factors 
Subjects in the FLS group were more likely to have secondary osteoporosis and 
glucocorticoids use. Secondary osteoporosis included type I insulin dependent diabetes, 
osteogenesis imperfecta, untreated long-standing hyperthyroidism, hypogonadism or 
premature menopause, malabsorption, and chronic liver disease. Upper extremity subjects 
were more likely to have rheumatoid arthritis. There was no difference in smoking, 
alcohol use, parental hip fracture, and fall history within the past two years between the 
groups (Table 5). In a subanalysis of only women, similar results were observed with the 
exception of secondary osteoporosis, which was no longer statistically significant (see 
Appendix).  
 
 
Table 5. Clinical risk factors 
 FLS UE Clinic P Value 
Currently smoking (%)    
          Yes 6.62 2.03 0.076 
          No 93.38 97.97  
Alcohol intake > 3 units per day (%)   0.504 
          Yes 2.21 4.05  
          No 97.79 95.95  
Parental hip fracture (%)   0.320 
          Yes 12.78 17.57  
          No 87.22 82.43  
Rheumatoid Arthritis (%)   0.004 
          Yes 3.01 12.84  
          No 96.99 87.16  
Glucocorticoid use (%)   0.004 
          Yes 16.30 5.41  
          No 83.70 94.59  
Secondary Osteoporosis (%)   0.007 
          Yes 18.66 7.53  
          No 81.34 92.47  
More than 2 falls in past year (%)   0.218 
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          Yes 21.97 15.54  
          No 78.03 84.46  
*FLS = fracture liaison service; UE = upper extremity 
*Results include both men and women 
*P values (two-sided) based on Fisher’s exact test 
 
 
 
Osteoporosis Evaluation and Treatment 
 Subjects in the FLS group were more likely to have had a DXA within the past 2 
years and take calcium supplements (P values 0.0001 and 0.0005, respectively). There 
was no difference in vitamin D supplementation, osteoporosis medication use, or 
estimated daily dietary calcium intake between the two groups (Table 6). Subanalysis of 
only women showed that the prevalence of osteoporosis medication use was similar 
between FLS and upper extremity groups (P value = 0.8766, see Appendix).  
 
Table 6. Osteoporosis Evaluation and Treatment 
 
 FLS UE Clinic P Value 
DXA within past 2 years (%)   < 0.001 
          Yes 93.02 37.16  
          No 6.98 62.84  
Calcium supplementation (%)   0.001 
          Yes 58.72 42.86  
          No 34.09 65.91  
Vitamin D supplementation (%)   0.790 
          Yes 66.07 63.97  
          No 33.93 36.03  
Estimate daily Ca intake (95% CI) 796.16 mg (737.90, 
859.01) 
827.94 mg (755.09, 
905.73) 
0.515 
Osteoporosis treatment (%)   0.079 
          Yes 47.06 34.88  
          No 52.94 65.12  
*CI = confidence interval; DXA = dual-energy x-ray absorptiometry; FLS = fracture liaison service; UE = 
upper extremity 
*Results include both men and women 
*P value (two-sided) based on Fisher’s exact test or Student’s t test 
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DXA T Scores 
 Significantly more FLS subjects had DXA scans than upper extremity subjects. In 
the FLS group, 112, 114, 116, and 21 patients had DXA results for the spine, hip, femoral 
neck, and distal radius, respectively. In the upper extremity group, 28, 29, 28, and 9 
patients had DXA results for the spine, hip, femoral neck, and distal radius, respectively. 
FLS subjects had a lower mean DXA T score in the distal radius when compared to upper 
extremity patients (Table 7). There was no difference in the mean DXA T score at the 
spine, femoral neck, and hip between groups (Figure 6). Of the FLS subjects who had 
DXA results, 42.4% and 50.4% of the patients had DXA T scores indicative of 
osteoporosis and osteopenia, respectively; 92.8% had abnormal DXA T scores. Of the 
upper extremity subjects who had DXA results, 35.5% and 48.4% of the subjects had 
DXA T scores indicative of osteoporosis and osteopenia, respectively; 83.9% had 
abnormal DXA results.  
 
Table 7. Mean DXA T scores 
 
 FLS UE Clinic P Value 
Mean DXA T Score (95% CI)    
     Spine -1.433 (-1.662, -1.204) -0.8857 (-1.582, -0.1897) 0.136 
     Hip -1.326 (-1.501, -1.152) -1.155 (-1.614, -0.6968) 0.412 
     Femoral neck -1.943 (-2.100, -1.786) -1.771 (-2.176, -1.367) 0.362 
     Distal radius -2.410 (-3.145, -1.674) -0.7556 (-2.013, 0.5017) 0.016 
*CI = confidence interval; DXA = dual-energy x-ray absorptiometry; FLS = fracture liaison service; UE = 
upper extremity 
*Results include both men and women 
*P value (two-sided) based on Student’s t test (parametric for spine, non-parametric for hip, femoral neck, 
and distal radius) 
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Figure 6. DXA T scores box and whisker plot 
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DISCUSSION 
 
 
In this study, the estimated FRAX 10-year probability of major osteoporotic 
fracture and hip fracture between two upper extremity patient cohorts were compared: 
upper extremity fragility fracture subjects over age 50 evaluated in the FLS clinic and 
similarly aged subjects evaluated in the upper extremity clinic for non-fracture 
conditions. 
The majority of subjects evaluated in the FLS and upper extremity (UE) clinic 
were older white non-Hispanic females. With respect to demographics and BMI, the UE 
fracture and UE non-fracture cohorts were similar, with the exception of more males in 
the UE non-fracture group. Low participation of men in FLS has been widely reported in 
the literature. A meta-analysis of over 25 FLS programs reported that women make up 
approximately 70.8 percent of all patients evaluated in FLSs (Ganda et al., 2013). The 
low percentage of men evaluated in FLSs suggests a potential greater osteoporosis care 
gap in men than women. 
In this study, results showed that UE fracture subjects had an overall significantly 
higher 10-year probability of fracture at the hip, spine, forearm, and shoulder compared 
to UE non-fracture subjects. However, when excluding history of fragility fracture, UE 
fracture and UE non-fracture subjects had a similar 10-year probability for fracture. This 
result suggests that UE fracture and UE non-fracture patients, with the exception of 
fragility fracture history, harbor similar fracture clinical risk factors. Although,  
differences in the prevalence of glucocorticoid use, rheumatoid arthritis, and secondary 
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osteoporosis between the two groups was evident. In addition, these results highlight the 
importance of fragility fractures as a main driver in subsequent fracture risk. Indeed, 
patients who sustain a UE distal radial fragility fracture have twice the relative risk for 
future hip fracture (Freedman, Kaplan, Bilker, Strom, & Lowe, 2000). 
In this study, UE fracture subjects on average had significantly lower BMD at the 
distal radius compared to UE non-fracture subjects, which was expected due to fragility 
fracture history among UE fracture subjects. UE fracture and UE non-fracture subjects 
had similar BMD T-scores at the spine, hip, and femoral neck. Among UE non-fracture 
subjects who had a DXA at any site, 35.5 percent and 48.4 percent of the DXA T scores 
were indicative of osteoporosis and osteopenia, respectively. Likewise, among UE 
fracture subjects who had a DXA at any site, 42.4 percent and 50.4 percent of the 
subjects had DXA T-scores indicative of osteoporosis and osteopenia, respectively. A 
total of 83.9 percent of available BMDs among UE non-fracture patients and 92.8 percent 
of available BMDs among UE fracture subjects were abnormal indicating an increased 
risk for fracture in these cohorts. 
Studies have demonstrated that abnormal BMD, either osteoporotic or osteopenic, 
is associated with an increased risk of fracture (Leslie et al., 2007). Individuals with 
osteoporotic BMD, T-scores less than -2.5, have the highest risk of fracture. However, 
the absolute number of fractures is highest among individuals who have osteopenic 
BMD, in part since the prevalence of osteopenia is higher than prevalence of osteoporosis 
(Cranney, Jamal, Tsang, Josse, & Leslie, 2007; Schuit et al., 2004; Siris et al., 2004). In 
this study, a majority of the UE fracture and UE non-fracture subjects with DXA 
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screening had osteopenic BMD. It is important to mention that only a limited number of 
UE non-fracture subjects had a BMD assessment. Only 40 percent of UE non-fracture 
subjects had a DXA at any of the sites. The low number of BMD assessments among 
these subjects suggests that they are under-screened for osteoporosis despite harboring 
similar fracture clinical risk factors as UE fracture patients. In addition, the proportion of 
UE non-fracture subjects reported being on osteoporosis therapy was low. Interestingly, 
the proportion of UE fracture subjects on osteoporosis therapy was also low and no 
different than UE non-fracture subjects, despite having higher rates of DXA BMD 
screening and being at a higher risk for subsequent fracture.  
Low rates of osteoporosis treatment initiation and adherence has been widely 
reported throughout the literature. It has been estimated that less than 20 percent of 
patients who sustain a fragility fracture actually start osteoporosis therapy within a year 
of their fracture (L. Giangregorio et al., 2006; John A. Kanis et al., 2014). Furthermore, 
among fragility fracture patients who do initiate osteoporosis therapy, very few are 
compliant enough with the therapy to optimally minimize their risk for subsequent 
fracture (Brookhart et al., 2007; Gold & Silverman, 2006).  
Studies investigating the reasons for low osteoporosis treatment initiation and 
compliance report cost of therapy, patient reluctance, time and cost of diagnosing 
osteoporosis, side effects of osteoporosis medications, skepticism of osteoporosis 
medication effectiveness, lack of access to BMD screening, and a lack of time for 
physicians to address secondary prevention as barriers to successful therapy (Elliot-
Gibson, Bogoch, Jamal, & Beaton, 2004). Furthermore, the media’s coverage of rare but 
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serious side effects associated with bisphosphonate use, which include atypical femur 
fracture, osteonecrosis of the jaw, and esophageal cancer, has further exacerbated 
patients’ reluctance to initiate and adhere to osteoporosis therapy, despite 
bisphosphonates’ proven effectiveness to treat osteoporosis. With the risk of subsequent 
fractures increasing after sustaining a fragility fracture, the diagnosis and treatment of 
osteoporosis in patients with fragility fractures provides the opportunity to prevent future 
fractures. Since fractures are typically first treated by orthopedic surgeons in fracture 
clinics or emergency departments, orthopedic surgeons serve as an early point of contact 
for fragility fracture patients and are in a unique position to narrow the osteoporosis care 
gap. Therefore, efforts to improve osteoporosis evaluation and treatment among fragility 
fracture patients may best be directed toward orthopedic surgeons. 
 Initiatives have been taken to attempt to close the osteoporosis care gap. In 2012, 
the International Osteoporosis Foundation (IOF) launched The Capture the Fracture 
Campaign with the goal of facilitating adoption of FLS globally to reduce the incidence 
of secondary fractures throughout the world (Akesson et al., 2013). To help promote FLS 
implementation globally, The Capture the Fracture Campaign aims to develop mentoring 
programs, FLS implementation guidelines and toolkits, and grant programs for 
developing FLS systems. The campaign aims to guide development of FLS programs 
worldwide through the Best Practice Framework (BPF), which is a collection of 
internationally endorsed standards for best practices in secondary fracture prevention. 
The BPF is comprised of 13 standards, which serves as an international benchmark for 
FLS standards. FLSs are assigned a level of achievement depending on how successful 
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they are in each of the 13 standards. FLS programs that register with The IOF Capture the 
Fracture Campaign are assigned an overall rating (Unclassified, Bronze, Silver, or Gold) 
based on two criteria: care across four key fragility fracture patient groups (hip fracture, 
inpatient fractures, outpatient fracture, and vertebral fracture) and FLS organizational 
characteristics. In addition, IOF registered FLSs will be awarded IOF approval and a 
placement on the Capture the Fracture Campaign website’s interactive map, which 
showcases each FLS to a global audience. In 2019, the total number of FLSs granted IOF 
approval grew to 225 from 35 different countries around the world, and this number is 
expected to grow. How effective these FLSs will be at reducing the osteoporosis care gap 
will need to be monitored. 
The limitations of this study include a limited sample size, use of patient reported 
data, lack of lab data among patients evaluated in the UE clinic, limited lab and BMD 
data among patients evaluated in the FLS, exclusion of individuals who did not speak 
English, and limited demographic information. Additional demographics data including 
distance from the hospital and area deprivation index scores would have improved 
characterization of this study population. Additionally, the study population was 
comprised of predominantly white non-Hispanic females, which limits the 
generalizability of our findings. The limits of the FRAX tool as a predictor for future hip 
fracture and major osteoporotic fracture serves as another limitation. Limitations of 
FRAX include uncertainty regarding the range of error with fracture risk, lack of 
validation with BMD measurements by technologies other than DXA, lack of extensive 
validation in patients treated for fracture, and limitation to only four ethnicities 
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(Caucasian, Black, Hispanic, Asian) in the United States (Leib et al., 2011). In addition, 
FRAX may underestimate fracture probability in individuals with multiple fractures, 
high-dose glucocorticoid exposure (defined as doses of prednisone or its equivalent 
greater than 7.5mg/day), severe vertebral fractures, parental history of non-hip fragility 
fractures, and diabetes mellitus (L. M. Giangregorio et al., 2012; Leib et al., 2011). 
In conclusion, history of fragility fracture is one of the main drivers for 
subsequent fracture risk. Our results indicate UE fracture and UE non-fracture patients 
share similar clinical risk factors for fracture. Closer osteoporosis evaluation for all older 
patients over 50 years old, including non-fracture patients, is warranted. Future studies 
should focus on addressing barriers to optimal osteoporosis management and the efficacy 
of implementation strategies designed to close the osteoporosis care gap. 
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APPENDIX 
 
Table 8. Data completion status (Men and Women) 
 FLS (n = 129) UE Clinic (n = 114) 
Complete FRAX variables 129 (100%) 114 (100%) 
Estimate daily Ca intake  129 (100%) 107 (94%) 
Vitamin D supplementation 107 (83%) 104 (91%) 
Calcium supplementation 103 (79%) 104 (91%) 
Currently smoking 129 (100%) 114 (100%) 
Alcohol intake > 3 units per 
day 
129 (100%) 114 (100%) 
Parental hip fracture 129 (100%) 114 (100%) 
Rheumatoid Arthritis 129 (100%) 114 (100%) 
Glucocorticoid use 129 (100%) 114 (100%) 
Secondary Osteoporosis 129 (100%) 113 (99%) 
Activity level in past 12 
months 
129 (100%) 114 (100%) 
DXA within past 2 years 125 (97%) 114 (100%) 
Osteoporosis treatment 99 (77%) 101 (86%) 
*The tables show number of data points available for each variable  
*To calculate a FRAX score, subjects must have an identifiable race and ethnicity; 
subjects who had race or ethnicity listed in EPIC as ‘unknown’, ‘other’, ‘declined’, or 
‘unavailable’ were excluded from the analytic cohort 
 
Table 9. Data completion status (Women Only) 
 FLS (n = 119) UE Clinic (n = 84) 
Complete FRAX** 119 (100%) 84 (100%) 
Estimate daily Ca intake  119 (100%) 81 (96%) 
Vitamin D supplementation 99 (83%) 84 (100%) 
Calcium supplementation 95 (90%) 84 (100%) 
Currently smoking 119 (100%) 84 (100%) 
Alcohol intake > 3 units per 
day 
119 (100%) 84 (100%) 
Parental hip fracture 119 (100%) 84 (100%) 
Rheumatoid Arthritis 119 (100%) 84 (100%) 
Glucocorticoid use 119 (100%) 84 (100%) 
Secondary Osteoporosis 119 (100%) 83 (99%) 
Activity level in past 12 
months 
119 (100%) 84 (100%) 
DXA within past 2 years 115 (97%) 84 (100%) 
Osteoporosis treatment 90 (76%) 75 (89%) 
*The tables show number of data points available for each variable 
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*To calculate a FRAX score, subjects must have an identifiable race and ethnicity; 
subjects who had race or ethnicity listed in EPIC as ‘unknown’, ‘other’, ‘declined’, or 
‘unavailable’ were excluded from the analytic cohort 
 
 
Table 10. Risk factors associated with fracture (Women Only) 
 
 FLS UE Clinic P value 
Currently smoking (%)   0.144 
          Yes 5.88 1.19  
          No 94.12 98.81  
Alcohol intake > 3 units per day (%)   0.999 
          Yes 1.68 2.38  
          No 98.32 97.62  
Parental hip fracture (%)   0.999 
          Yes 12.61 13.10  
          No 87.39 86.90  
Rheumatoid Arthritis (%)   0.044 
          Yes 3.36 10.71  
          No 96.64 89.29  
Glucocorticoid use (%)   0.002 
          Yes 17.65 3.57  
          No 82.35 96.43  
Secondary Osteoporosis (%)   0.214 
          Yes 16.81 9.64  
          No 83.19 90.36  
More than 2 falls in past year (%)   0.483 
          Yes 22.22 35.59  
          No 77.78 43.13  
*FLS = fracture liaison service; UE = upper extremity 
*Results include both men and women 
*P values (two-sided) based on Fisher’s exact test 
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Table 11. Osteoporosis evaluation and treatment (Women Only) 
 
 FLS UE Clinic P value 
Estimate daily Ca intake (95% CI) 783.43mg (721.11, 
851.14) 
807.24 (711.21, 
916.22) 
0.683 
Vitamin D supplementation (%)   0.635 
          Yes 66.67 70.24  
          No 33.33 29.76  
Calcium supplementation (%)   0.053 
          Yes 61.05 46.43  
          No 38.95 53.57  
DXA within past 2 years (%)   < 0.001 
          Yes 93.04 51.19  
          No 6.96 48.81  
Osteoporosis treatment (%)   0.877 
          Yes 52.22 50.67  
          No 47.78 49.33  
*CI = confidence interval; DXA = dual-energy x-ray absorptiometry; FLS = fracture 
liaison service; UE = upper extremity 
*Results include both men and women 
*P value (two-sided) based on Fisher’s exact test or Student’s t test 
 
 
 
Table 12. Number of DXA T-scores available (Men and Women) 
 
 FLS (n = 129) UE Clinic (n = 114) 
Spine 112 (87%) 28 (25%) 
Hip 114 (88%) 29 (25%) 
Femoral neck 116 (90%) 28 (25%) 
Distal Radius 21 (16%) 9 (8%) 
*FLS = fracture liaison service; UE = upper extremity 
*Number of analytic cohort that has DXA results 
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